Today: 20 May 2026
Browse Category

NASDAQ:MNMD 18 October 2025

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed Stock Rockets on Breakthrough LSD Anxiety Data – Analysts Eye 100% Upside

MindMed shares hit a 52-week high of $13.09 on Oct. 14, up 68% year-to-date, after its LSD-derived drug MM120 showed 48% remission in a Phase 2b anxiety trial and received FDA Breakthrough Therapy status. The company holds $237.9 million in cash and is running three Phase 3 studies, with topline results due in 2026. Most analysts rate MNMD a “Moderate Buy” with an average 12-month target near $28.
18 October 2025
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Soars 15% to 52-Week High on Psychedelic Breakthrough – What’s Next for MNMD?

MindMed (NASDAQ: MNMD) closed at $13.65 on Oct. 17, up 14.6% in one day and 68% year-to-date, after its LSD-based therapy MM120 showed strong Phase 2b results for Generalized Anxiety Disorder. The FDA granted Breakthrough Therapy status to MM120, with three Phase 3 trials underway. Needham & Co. initiated coverage with a Buy rating and $28 target. MindMed holds $237.9 million in cash, funding operations into 2027.
MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed Stock Skyrockets on Psychedelic Breakthroughs – What’s Driving the MNMD Surge?

MindMed shares hit a 52-week high of $13.09 this week after its LSD-based drug MM120 showed strong Phase 2b results for generalized anxiety disorder and received FDA Breakthrough Therapy designation. The stock is up about 68% year-to-date. Analysts set average price targets near $27.83. MindMed holds $237.9 million in cash, funding operations into 2027.

Stock Market Today

  • Euronext Reports Eighth Consecutive Quarter of Double-Digit Growth in Q1 2026
    May 20, 2026, 4:43 AM EDT. Euronext posted strong Q1 2026 results, marking its eighth straight quarter of double-digit growth. The exchange operator reported record performance in non-volume related revenues, underscoring its diversified income streams beyond trading volumes. This robust start to the year highlights Euronext's expanding role in European financial markets, supported by strategic investments and product offerings. The results reflect continued market confidence amid evolving economic conditions.

Latest articles

Chewy Shares Slide on CEO Talk of “Stretched Consumer”

Chewy Shares Slide on CEO Talk of “Stretched Consumer”

20 May 2026
Chewy Inc. shares dropped 9.1% to $19.66 Tuesday after CEO Sumit Singh warned U.S. consumers are more financially strained than earlier this year. The decline put Chewy near its 52-week low ahead of its June 10 earnings report. Singh made the comments at a J.P. Morgan conference, citing multiple data points on weaker consumer demand. Petco fell 2.9%, while BARK rose 7.5% and Amazon slipped 2.1%.
Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

Meiwu Technology Stock Jumps Again After 97% Surge: Why WNW Is Moving Now

20 May 2026
Meiwu Technology shares jumped 97% to $4.75 Tuesday and rose another 12% premarket after the company raised $15.65 million in a private share sale to fund an AI skincare platform. The rally follows a 1-for-100 reverse share split in April and earlier $14 million direct offering. Meiwu warned its new platform is early-stage and faces regulatory risks.
Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

Astera Labs Stock Surges: The AI Networking Bet Traders Are Chasing Before Nvidia Results

20 May 2026
Astera Labs shares rose 13.3% to $244.26 on Tuesday after management outlined a faster ramp for its Scorpio X fabric switches and optical networking tied to Nvidia’s NVLink Fusion. The move followed presentations at J.P. Morgan’s tech conference and comes ahead of Nvidia’s earnings Wednesday. Astera’s first-quarter revenue jumped 93% to $308.4 million, with second-quarter guidance above analyst forecasts.
Go toTop